Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • News
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • News
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. Plasmids
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

Plasmids

[0564-IB47171] I-BLUE MINI PLASMID Test - 100 preps
I-BLUE MINI PLASMID Test - 100 preps
439.00 € 439.0 EUR
[0399-CSB-CL5129CMB] Hypothetical protein WP_003477458 459bp pUC vector - 100ug. plasmid + 200ul glycerol
Hypothetical protein WP_003477458 459bp pUC vector - 100ug. plasmid + 200ul glycerol
415.00 € 415.0 EUR
[0399-CSB-CL5128CMB] Hypothetical protein BG908_05820 201bp in pUC vector - 100ug. plasmid + 200ul glycerol
Hypothetical protein BG908_05820 201bp in pUC vector - 100ug. plasmid + 200ul glycerol
370.00 € 370.0 EUR
[0322-SR10068PA-1] Human Alpha-Actin 2, ACTA2 Differentiation Reporter (pGreenZeo, plasmid) - 10 ug.
Human Alpha-Actin 2, ACTA2 Differentiation Reporter (pGreenZeo, plasmid) - 10 ug.
3,000.00 € 3000.0 EUR
[0639-abx988152] Rat PARM1 shRNA Plasmid - 150 ug.
Rat PARM1 shRNA Plasmid - 150 ug.
1,012.00 € 1012.0 EUR
[0184-FAPDE-002-1] Plasmid DNA Extraction Midi Test - 50
Plasmid DNA Extraction Midi Test - 50
342.50 € 342.5 EUR
[0184-FAPDE003-1] Plasmid DNA Extraction Maxi Test (20 prep)
Plasmid DNA Extraction Maxi Test (20 prep)
535.00 € 535.0 EUR
[0820-PVT4003-2ug.] PVT4003 - pPIC9K Plasmid 2ug.
PVT4003 - pPIC9K Plasmid 2ug.
360.00 € 360.0 EUR
[0820-PVT2341] PUMVC PLASMID
PUMVC PLASMID
409.00 € 409.0 EUR
[0820-PVT12233] PTXB1-TN5 Plasmid - 2ug.
PTXB1-TN5 Plasmid - 2ug.
996.15 € 996.15 EUR
[0820-PVT1032] PTT5 PLASMID - 2 µg
PTT5 PLASMID - 2 µg
457.00 € 457.0 EUR
[0820-PVTB00948-3a] PPLK/GFP+PURO-ATG4B SHRNA-1 PLASMID
PPLK/GFP+PURO-ATG4B SHRNA-1 PLASMID
495.00 € 495.0 EUR
[0820-PVT21526] PMSP3535 plasmid - 2 ug.
PMSP3535 plasmid - 2 ug.
425.00 € 425.0 EUR
[0820-PVT2304] PLVX- IRES- PURO Plasmid
PLVX- IRES- PURO Plasmid
454.00 € 454.0 EUR
[0820-PVT6002] PKD4 plasmid - 2 ug.
PKD4 plasmid - 2 ug.
422.50 € 422.5 EUR
[0820-PVT6008] PK18MOBSACB PLASMID 2ug.
PK18MOBSACB PLASMID 2ug.
410.00 € 410.0 EUR
[0820-PVT1229] PIRES2- DSRED- EXPRESS PLASMID 2ug.
PIRES2- DSRED- EXPRESS PLASMID 2ug.
296.00 € 296.0 EUR
[0820-PVT15896-2ug.] PGL3-NFKB PLASMID 2ug.
PGL3-NFKB PLASMID 2ug.
339.00 € 339.0 EUR
[0820-PVT47606] PFREE PLASMID, 2 ug.
PFREE PLASMID, 2 ug.
536.00 € 536.0 EUR
[0820-PVT23110] PFC330 plasmid - 2 ug.
PFC330 plasmid - 2 ug.
486.00 € 486.0 EUR
  • 1
  • 2
  • 3
  • 4
  • 5

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)